Haleon plc (HLN) is a Drug Manufacturers - Specialty & Generic company in the Healthcare sector, currently trading at $9.70. It has a SharesGrow Score of 63/100, indicating a above average investment profile with 4 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of HLN = $16.99 (+75.2% from the current price, the stock appears undervalued). Analyst consensus target is HLN = $10 (+5.2% upside).
Valuation: HLN trades at a trailing Price-to-Earnings (P/E) of 31.7 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 3.25.
Financials: revenue is $10.8B, -0.2%/yr average growth. Net income is $1.6B, growing at +16.5%/yr. Net profit margin is 15.1% (healthy). Gross margin is 64.8% (+4.2 pp trend).
Balance sheet: total debt is $8.6B against $16.4B equity (Debt-to-Equity (D/E) ratio 0.52, moderate). Current ratio is 0.92 (tight liquidity). Debt-to-assets is 26.4%. Total assets: $32.6B.
Analyst outlook: 3 / 4 analysts rate HLN as buy (75%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 33/100 (Fail), Growth 48/100 (Partial), Past 100/100 (Pass), Health 33/100 (Fail), Moat 84/100 (Pass), Future 73/100 (Pass), Income 70/100 (Pass).
